Hepatitis C Virus Infection Suppresses the Interferon Response in the Liver of the Human Hepatocyte Chimeric Mouse

Background and Aims Recent studies indicate that hepatitis C virus (HCV) can modulate the expression of various genes including those involved in interferon signaling, and up-regulation of interferon-stimulated genes by HCV was reported to be strongly associated with treatment outcome. To expand our understanding of the molecular mechanism underlying treatment resistance, we analyzed the direct effects of interferon and/or HCV infection under immunodeficient conditions using cDNA microarray analysis of human hepatocyte chimeric mice. Methods Human serum containing HCV genotype 1b was injected into human hepatocyte chimeric mice. IFN-α was administered 8 weeks after inoculation, and 6 hours later human hepatocytes in the mouse livers were collected for microarray analysis. Results HCV infection induced a more than 3-fold change in the expression of 181 genes, especially genes related to Organismal Injury and Abnormalities, such as fibrosis or injury of the liver (P = 5.90E-16 ∼ 3.66E-03). IFN administration induced more than 3-fold up-regulation in the expression of 152 genes. Marked induction was observed in the anti-fibrotic chemokines such as CXCL9, suggesting that IFN treatment might lead not only to HCV eradication but also prevention and repair of liver fibrosis. HCV infection appeared to suppress interferon signaling via significant reduction in interferon-induced gene expression in several genes of the IFN signaling pathway, including Mx1, STAT1, and several members of the CXCL and IFI families (P = 6.0E-12). Genes associated with Antimicrobial Response and Inflammatory Response were also significantly repressed (P = 5.22×10−10 ∼ 1.95×10−2). Conclusions These results provide molecular insights into possible mechanisms used by HCV to evade innate immune responses, as well as novel therapeutic targets and a potential new indication for interferon therapy.

[1]  B. Bay,et al.  Modulation of metallothionein isoforms is associated with collagen deposition in proliferating keloid fibroblasts in vitro , 2010, Experimental dermatology.

[2]  M. Imamura,et al.  Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy , 2010, Antiviral therapy.

[3]  K. Horimoto,et al.  Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. , 2010, Gastroenterology.

[4]  A. Koike,et al.  Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.

[5]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[6]  F. Tacke,et al.  Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. , 2009, Gastroenterology.

[7]  M. Daveau,et al.  Novel serum markers of fibrosis progression for the follow-up of hepatitis C virus-infected patients. , 2009, The American journal of pathology.

[8]  Yoshiyuki Suzuki,et al.  Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads , 2009, Digestive Diseases and Sciences.

[9]  M. Katze,et al.  HCV Induces Oxidative and ER Stress, and Sensitizes Infected Cells to Apoptosis in SCID/Alb-uPA Mice , 2009, PLoS pathogens.

[10]  P. Bioulac-Sage,et al.  Transient and etiology-related transcription regulation in cirrhosis prior to hepatocellular carcinoma occurrence. , 2009, World journal of gastroenterology.

[11]  M. Imamura,et al.  Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice. , 2008, The Journal of general virology.

[12]  Edward J Oakeley,et al.  Interferon signaling and treatment outcome in chronic hepatitis C , 2008, Proceedings of the National Academy of Sciences.

[13]  K. Koike,et al.  PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. , 2008, The Journal of clinical investigation.

[14]  M. Cam,et al.  Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response , 2007, Hepatology.

[15]  Yoshiyuki Suzuki,et al.  Prediction of Response to Pegylated Interferon and Ribavirin in Hepatitis C by Polymorphisms in the Viral Core Protein and Very Early Dynamics of Viremia , 2007, Intervirology.

[16]  S. Akira,et al.  Hepatitis C Virus Nonstructural Protein 5A Modulates the Toll-Like Receptor-MyD88-Dependent Signaling Pathway in Macrophage Cell Lines , 2007, Journal of Virology.

[17]  M. Imamura,et al.  Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon , 2007, FEBS letters.

[18]  M. Imamura,et al.  Dual effect of APOBEC3G on Hepatitis B virus. , 2007, The Journal of general virology.

[19]  Keiji Tanaka,et al.  Critical role of PA28γ in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis , 2007, Proceedings of the National Academy of Sciences.

[20]  M. Honda,et al.  Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C , 2006, Hepatology.

[21]  K. Shimotohno,et al.  High expression of APOBEC3G in patients infected with hepatitis C virus , 2006, Journal of Molecular Histology.

[22]  H. Conjeevaram,et al.  Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. , 2006, Gastroenterology.

[23]  M. Katze,et al.  Host-Specific Response to HCV Infection in the Chimeric SCID-beige/Alb-uPA Mouse Model: Role of the Innate Antiviral Immune Response , 2006, PLoS pathogens.

[24]  S. Wain-Hobson,et al.  Interferon‐inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication , 2006, Hepatology.

[25]  Deborah Chavez,et al.  Genomic response to interferon‐α in chimpanzees: Implications of rapid downregulation for hepatitis C kinetics , 2006, Hepatology.

[26]  R. Bartenschlager,et al.  E2 of Hepatitis C Virus Inhibits Apoptosis1 , 2005, The Journal of Immunology.

[27]  Zhijian J. Chen,et al.  Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T. Asselah,et al.  Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. , 2005, Gastroenterology.

[29]  M. Imamura,et al.  Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus , 2005, Hepatology.

[30]  Osamu Takeuchi,et al.  IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction , 2005, Nature Immunology.

[31]  Z. Zhai,et al.  VISA Is an Adapter Protein Required for Virus-Triggered IFN-β Signaling , 2005 .

[32]  Zhijian J. Chen,et al.  Identification and Characterization of MAVS, a Mitochondrial Antiviral Signaling Protein that Activates NF-κB and IRF3 , 2005, Cell.

[33]  M. Malim,et al.  APOBEC‐mediated interference with hepadnavirus production , 2005, Hepatology.

[34]  Yoshiyuki Suzuki,et al.  Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 1b High Viral Load and Non-Virological Response to Interferon-Ribavirin Combination Therapy , 2005, Intervirology.

[35]  M. Imamura,et al.  G to A hypermutation of hepatitis B virus , 2005, Hepatology.

[36]  T. Asahara,et al.  Near completely humanized liver in mice shows human-type metabolic responses to drugs. , 2004, The American journal of pathology.

[37]  M. Malim,et al.  APOBEC-Mediated Editing of Viral RNA , 2004, Science.

[38]  G. Ippolito,et al.  HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. , 2004, Journal of hepatology.

[39]  Michel Henry,et al.  APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. , 2004, Nucleic acids research.

[40]  Keiji Tanaka,et al.  Proteasome Activator PA28γ-Dependent Nuclear Retention and Degradation of Hepatitis C Virus Core Protein , 2003, Journal of Virology.

[41]  R. König,et al.  Species-Specific Exclusion of APOBEC3G from HIV-1 Virions by Vif , 2003, Cell.

[42]  Gersende Caron,et al.  Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts , 2003, Nature.

[43]  Hui Zhang,et al.  The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA , 2003, Nature.

[44]  J. Hoofnagle,et al.  Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin , 2003, Hepatology.

[45]  F. Clavel,et al.  Hypermutation of HIV-1 DNA in the Absence of the Vif Protein , 2003, Science.

[46]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[47]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[48]  M. Grace,et al.  Interferon‐α as an immunotherapeutic protein , 2002, Journal of Leukocyte Biology.

[49]  C. Samuel,et al.  Antiviral Actions of Interferons , 2001, Clinical Microbiology Reviews.

[50]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[51]  D. Tyrrell,et al.  Hepatitis C virus replication in mice with chimeric human livers , 2001, Nature Medicine.

[52]  K. Koike,et al.  Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. , 2001, Cancer research.

[53]  L. Platanias,et al.  Signaling pathways activated by interferons. , 1999, Experimental hematology.

[54]  P Parham,et al.  Analysis of a successful immune response against hepatitis C virus. , 1999, Immunity.

[55]  Yoshiharu Matsuura,et al.  The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice , 1998, Nature Medicine.

[56]  M J Clemens,et al.  The double-stranded RNA-dependent protein kinase PKR: structure and function. , 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[57]  K Koike,et al.  Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. , 1997, The Journal of general virology.

[58]  N Enomoto,et al.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. , 1996, The New England journal of medicine.

[59]  R. Silverman,et al.  2-5A-dependent RNase Molecules Dimerize during Activation by 2-5A (*) , 1995, The Journal of Biological Chemistry.

[60]  P. Staeheli,et al.  Mx proteins: GTPases with antiviral activity. , 1993, Trends in cell biology.

[61]  R. Purcell,et al.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. , 1989, The New England journal of medicine.

[62]  平賀 伸彦 Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon , 2008 .

[63]  Z. Zhai,et al.  VISA is an adapter protein required for virus-triggered IFN-beta signaling. , 2005, Molecular cell.

[64]  Zhijian J. Chen,et al.  Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. , 2005, Cell.

[65]  Keiji Tanaka,et al.  Proteasome activator PA28gamma-dependent nuclear retention and degradation of hepatitis C virus core protein. , 2003, Journal of virology.

[66]  Y. Jeong,et al.  Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection , 2003 .

[67]  M. Grace,et al.  Interferon-alpha as an immunotherapeutic protein. , 2002, Journal of leukocyte biology.